Cotrimoxazole for Typhoid Fever
Cotrimoxazole (trimethoprim-sulfamethoxazole) should be reserved as an alternative oral agent for typhoid fever caused by fully susceptible Salmonella Typhi strains when fluoroquinolones cannot be used, but it is no longer appropriate for first-line therapy due to widespread resistance. 1
When Cotrimoxazole Is Appropriate
Clinical Scenarios for Use
- Fully susceptible strains only: WHO guidelines position cotrimoxazole alongside chloramphenicol and amoxicillin as alternative oral agents when fluoroquinolones are contraindicated or unavailable 1
- Documented susceptibility required: Given that multidrug resistance (MDR) affects 20% of isolates and extensively drug-resistant (XDR) strains now comprise 47% of cases in some regions, treatment must be guided by culture and sensitivity testing 2
- Not for quinolone-resistant strains: When fluoroquinolone resistance is present, azithromycin or ceftriaxone become the preferred options 1
Historical Context and Current Limitations
While cotrimoxazole demonstrated efficacy in older studies from the 1970s-1980s with defervescence in 3-8 days 3, 4, the emergence of plasmid-mediated resistance has dramatically reduced its utility 5. The drug was particularly effective against chloramphenicol-resistant strains in Vietnam and Indonesia during that era 4, 6, but contemporary resistance patterns have shifted the treatment landscape 7.
Recommended Dosing Regimen
Adults
- Standard dose: 1600 mg sulfamethoxazole + 320 mg trimethoprim (4 teaspoonfuls or 20 mL of oral suspension) every 12 hours 8
- Duration: 14 days for typhoid fever (extrapolated from historical studies showing 10-14 day courses) 3, 4
Pediatric Patients (≥2 months old)
- Weight-based dosing: 40 mg/kg/day sulfamethoxazole + 8 mg/kg/day trimethoprim, divided every 12 hours 8
- Duration: 14 days 9
- Not recommended: Children under 2 months of age 8
Renal Impairment Adjustments
- CrCl >30 mL/min: Standard dosing 8
- CrCl 15-30 mL/min: Reduce to half the usual regimen 8
- CrCl <15 mL/min: Use not recommended 8
Critical Pitfalls and Caveats
Resistance Surveillance
- Empiric therapy is dangerous: With 75% of isolates showing resistance to cotrimoxazole in some historical cohorts 6 and contemporary MDR/XDR rates approaching 67% combined 2, empiric use without susceptibility data risks treatment failure
- Geographic variation: Resistance patterns vary dramatically by region, making local antibiograms essential 2, 5
Special Populations
- G6PD deficiency: While one study showed cotrimoxazole could be used cautiously in G6PD-deficient children with close monitoring for hemolysis 9, the risk-benefit ratio must be carefully considered
- Treatment failure patterns: Historical data showed paradoxically higher failure rates with susceptible strains compared to resistant strains when using cotrimoxazole 6, suggesting host factors play important roles
Comparative Effectiveness
- Inferior to fluoroquinolones: Even for susceptible strains, ofloxacin achieved significantly faster clinical resolution and culture clearance than cotrimoxazole in head-to-head trials 10
- Slower defervescence: Mean time to defervescence with cotrimoxazole (3-8 days) 3, 9 compares unfavorably to azithromycin and newer fluoroquinolones 7
Modern Treatment Algorithm
- Obtain blood cultures before initiating therapy 2
- Check local resistance patterns or await susceptibility results 5
- If fully susceptible strain confirmed and fluoroquinolones contraindicated → cotrimoxazole is acceptable 1
- If quinolone-resistant or MDR/XDR → use azithromycin (preferred) or ceftriaxone 1
- Monitor clinical response within 3-5 days; lack of defervescence suggests resistance or treatment failure 3, 10